Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.
Tokuoka K, Muramoto K, Sakanaka K, Yoshihara K, Yamamoto S, Imai Y, Iwatani K, Tashiro K, Murakami M, Harada T, Hayashimoto T, Umemori M, Kimura T, Shimomura T, Urabe F. Tokuoka K, et al. Among authors: imai y. Int Cancer Conf J. 2024 Aug 31;13(4):510-514. doi: 10.1007/s13691-024-00720-3. eCollection 2024 Oct. Int Cancer Conf J. 2024. PMID: 39398921
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Fukuokaya W, et al. Among authors: imai y. Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36102985 Free PMC article.
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M, Fukuokaya W, Yanagisawa T, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Oyama Y, Abe H, Miki J, Kimura T. Hashimoto M, et al. Among authors: imai y. Int J Clin Oncol. 2024 May;29(5):612-619. doi: 10.1007/s10147-024-02482-7. Epub 2024 Mar 2. Int J Clin Oncol. 2024. PMID: 38430304
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C, Urabe F, Fukuokaya W, Iwatani K, Imai Y, Yasue K, Mori K, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Yuen SKK, Teoh JY, Shimomura T, Yamada H, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Narita C, et al. Among authors: imai y. Clin Genitourin Cancer. 2024 Jun;22(3):102082. doi: 10.1016/j.clgc.2024.102082. Epub 2024 Mar 21. Clin Genitourin Cancer. 2024. PMID: 38641443
Does age impact clinical outcomes of radical nephroureterectomy in the elderly?-results from a multicenter retrospective study.
Ishikawa M, Muramoto K, Yoshihara K, Yamamoto S, Miyajima K, Iwatani K, Imai Y, Kayano S, Ito K, Igarashi T, Mori K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Sasaki T, Sato S, Shimomura T, Furuta A, Miki J, Urabe F, Kimura T. Ishikawa M, et al. Among authors: imai y. Transl Androl Urol. 2024 May 31;13(5):688-698. doi: 10.21037/tau-24-37. Epub 2024 May 22. Transl Androl Urol. 2024. PMID: 38855598 Free PMC article.
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Shimomura T, Yamada H, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Urabe F, et al. Among authors: imai y. Int J Urol. 2024 Nov;31(11):1248-1255. doi: 10.1111/iju.15546. Epub 2024 Jul 19. Int J Urol. 2024. PMID: 39031448
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, Imai Y, Iwatani K, Ito K, Urabe F, Tsuzuki S, Kimura S, Terada N, Mukai S, Oyama Y, Abe H, Kamoto T, Azuma H, Miki J, Egawa S. Fukuokaya W, et al. Among authors: imai y. Urol Oncol. 2022 Jul;40(7):346.e1-346.e8. doi: 10.1016/j.urolonc.2022.02.020. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346571
4,632 results